Ursodeoxycholic Acid (UDCA) Powder (128-13-2)
Product Name: Ursodeoxycholic acid
Synonyms: 3,7-Dihydroxycholan-24-oic acid; 3alpha,7beta-Dihydroxy-6beta-cholan-24-oic acid; Ursodiol; 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol; (3alpha,5beta,7alpha)-3,7-dihydroxycholan-24-oic acid;
CAS:128-13-2
EINECS: 204-879-3
Assay: 99%
Appearance: white powder
Packing: 25KG/ cardboard bucket can be split
Physicochemical properties: soluble in ethanol, insoluble in chloroform; soluble in glacial acetic acid, dissolved in sodium hydroxide solution.
Category: pharmaceutical raw materials
Industry: Medicine
Extension products: Ursodeoxycholic Acid Capules, Ursodeoxycholic Acid Tablets
Use: increases bile acid secretion, and the changes of bile components, reduce cholesterol in bile and cholesterol, is conducive to the gradual dissolution of cholesterol gallstones, used for surgical treatment of cholesterol stones, stones but can not dissolve bile pigment stones and mixed stones and roentgenopaque. Cholecystitis. Biliary tract inflammation and dyspepsia are also effective.
Ursodeoxycholic Acid (UDCA) Description:
Ursodeoxycholic acid, also known as ursodiol (USAN) and the abbreviation UDCA, from the root-word for bear urso, as bear bile contains the substance, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria.
Ursodeoxycholic Acid (UDCA) Application:
Used as an anticholelithogenic . Epimer with Chenodiol with respect to the hydroxyl group at C7 Gallstone dissolving drugs. Mainly used in the treatment of inoperable cholesterol gallstones, especially basic gallbladder function properly, stones 15mm or less in diameter, through X-ray, non-calcified cholesterol stones floating high cure rate. Of toxic hepatitis, cholecystitis, primary sclerosing cholangitis, primary biliary cirrhosis of liver also have some therapeutic effect. Improve the efficacy of α- interferon treatment of chronic hepatitis C. Diarrhea, constipation rare, allergic reactions, itching, headache, dizziness, stomach pain, pancreatitis, and bradycardia. Biliary complete obstruction and severe liver dysfunction and pregnant women hanged.
Ursodeoxycholic Acid (UDCA) Use:
1. Reduction in gallstone formation, either in patients with gallstones unfit for cholecystectomy, or obese patients undergoing rapid weight loss to prevent gallstone formation.
2. For the treatment of primary biliary cholangitis (PBC).
3. To aim to improve bile flow in patients with cystic fibrosis controversial.
4. In newborn infants with impaired bile flow.
5. After bariatric surgery, to prevent cholelithiasis due to the rapid weight loss with biliary cholesterol oversaturation and also biliary diskinesia secondary to abnormalities in cholecystokinin and biliary enervation.
Ursodeoxycholic Acid (UDCA) COA:
| Item |
Specification |
| Appearance |
White or almost white powder |
| Identification-UDCA |
A. Comparable IR absorption with the reference.
B. The spot is similar in position,colour and size with the reference spot
C. A blue-green precipitate occurs |
| Melting Point |
About 202 |
| Specific optical rotation |
+58.0º ~ +62.0º |
| Heavy Metal |
NMT 10ppm |
| Loss on drying |
NMT 1.0% |
| Sulphated ash |
NMT 0.10% |
Related substances(TLC )
-Lithocholic acid
-Chenodeoxycholic acid
-Cholic acid
-Any other single impurity |
NMT 0.10%
NMT 1.0%
NMT 0.5%
NMT 0.25% |
| Assay (C 24 H 40 O 4 ) |
99.0% ~ 101.0%(as dry basis) |
Ursodeoxycholic Acid (UDCA) HPLC:
Rowe Chen
Sales01
Sales Manager